Oppenheimer analyst Ken Wong notes that Outperform-rated Veeva (VEEV) announced that Merck (MRK) has committed to Vault CRM. This marks Veeva’s sixth enterprise pharma Vault CRM commitment. The company is gaining momentum leading up to the September GA of Salesforce’s Life Sciences Cloud for Customer Engagement. The firm believes the announcement is incrementally positive, but it was broadly expected Veeva would secure a commitment from Merck, given its long-term strategic partnership with the company, and industry chatter that an agreement was an inevitability. That said, Merck is the largest pharma company globally by revenue and a strong endorsement for Vault CRM. Extrapolating current commitments would imply about 75% share for Veeva, which is still within investor expectations, Oppenheimer adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems’ Strong Market Position and Growth Potential: A Buy Rating by Dylan Becker
- Veeva announces Merck committed to Veeva Vault CRM
- Veeva Systems: Strategic Positioning and Growth Potential with Crossix Integration
- Veeva Systems Inc. Advances Infant Nutrition with Glycoprotein Formula Study
- Veeva Systems’ Role in Pioneering Study on Nutrition and Early Development